Skip to content

Study · Non-randomized trial · n = 16 · 1991

20 results

Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women.

Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C

The Journal of clinical endocrinology and metabolism1 Feb 1991Cited by 38 (Europe PMC)

PMID1846873 (opens in a new tab)DOI10.1210/jcem-72-2-344 (opens in a new tab)PepBankPUB-01846873
Source linkPubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In premenopausal and early postmenopausal women, total serum calcium changed significantly after all four sCT administrations (50, 100 and 200 IU intranasal and 50 IU intramuscular; P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum calcium changed significantly after each of the four sCT administrations.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedTotal serum calcium
    Study

    n = 16

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    50 IU, 100 IU and 200 IU intranasal; 50 IU intramuscular · intranasal and intramuscularAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  2. 02HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after all four sCT administrations (50, 100 and 200 IU intranasal and 50 IU intramuscular; P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after each of the four sCT administrations.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum beta-endorphin
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    50 IU, 100 IU and 200 IU intranasal; 50 IU intramuscular · intranasal and intramuscularAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  3. 03HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, the two highest intranasal sCT doses (100 IU and 200 IU) increased cAMP by 10% (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, the two highest intranasal sCT doses increased cAMP.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasecAMP
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 IU and 200 IU · intranasalAs given in this study (human).

    Measurements

    cAMP increase
    10%
    two highest intranasal doses (100 IU and 200 IU)

    Source sentences

    Summary
    After the two highest intranasal and the im doses cAMP increased 10% and 35%, respectively (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  4. 04HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, intramuscular sCT increased cAMP by 35% (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, intramuscular sCT increased cAMP.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasecAMP
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    50 IU · intramuscularAs given in this study (human).

    Measurements

    cAMP increase
    35%
    50 IU intramuscular

    Source sentences

    Summary
    After the two highest intranasal and the im doses cAMP increased 10% and 35%, respectively (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  5. 05HumanNon-randomized trialPharmacokinetics

    In premenopausal and early postmenopausal women, plasma sCT increased significantly after 100 IU and 200 IU intranasal and 50 IU intramuscular sCT, but not after 50 IU intranasal (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, plasma sCT rose significantly after most sCT doses, but not after 50 IU intranasal.

    Peptide
    Calcitonin-salmon
    Outcome
    MixedPlasma sCT
    Study

    n = 16

    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    50 IU, 100 IU and 200 IU intranasal; 50 IU intramuscular · intranasal and intramuscularAs given in this study (human).

    Source sentences

    Summary
    All administrations except the 50 IU intranasal dose produced significant increases in plasma sCT (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  6. 06HumanNon-randomized trialActivity measurement

    In premenopausal and early postmenopausal women, serum calcium concentration-time areas showed a significant sCT dose response over 120-240 min (P less than 0.01-0.001).

    In plain wordsIn premenopausal and early postmenopausal women, serum calcium responses varied significantly with the sCT dose.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum calcium dose response
    Study

    n = 16

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    50 IU, 100 IU and 200 IU intranasal; 50 IU intramuscular · intranasal and intramuscularAs given in this study (human).

    Source sentences

    Summary
    The areas under the concentration-time curves, calculated for the period with the maximal changes (i.e. 120-240 min), illustrated a significant dose-related response in total serum calcium, beta-endorphin, and sCT (P less than 0.01-0.001).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  7. 07HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, beta-endorphin concentration-time areas showed a significant sCT dose response over 120-240 min (P less than 0.01-0.001).

    In plain wordsIn premenopausal and early postmenopausal women, beta-endorphin responses varied significantly with the sCT dose.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedBeta-endorphin dose response
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    50 IU, 100 IU and 200 IU intranasal; 50 IU intramuscular · intranasal and intramuscularAs given in this study (human).

    Source sentences

    Summary
    The areas under the concentration-time curves, calculated for the period with the maximal changes (i.e. 120-240 min), illustrated a significant dose-related response in total serum calcium, beta-endorphin, and sCT (P less than 0.01-0.001).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  8. 08HumanNon-randomized trialPharmacokinetics

    In premenopausal and early postmenopausal women, sCT concentration-time areas showed a significant dose response over 120-240 min (P less than 0.01-0.001).

    In plain wordsIn premenopausal and early postmenopausal women, sCT exposure varied significantly with the dose.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedsCT dose response
    Study

    n = 16

    Comparator
    other sCT dose levels
    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    50, 100 and 200 IU intranasal; 50 IU intramuscular · intranasal and intramuscularAs given in this study (human).

    Source sentences

    Summary
    The areas under the concentration-time curves, calculated for the period with the maximal changes (i.e. 120-240 min), illustrated a significant dose-related response in total serum calcium, beta-endorphin, and sCT (P less than 0.01-0.001).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  9. 09HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, intramuscular sCT produced a higher cAMP response than the lowest intranasal dose (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, intramuscular sCT increased cAMP more than the lowest intranasal dose.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasecAMP response versus intranasal 50 IU
    Study

    n = 16

    Comparator
    50 IU intranasal sCT
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    50 IU · intramuscularAs given in this study (human).

    Source sentences

    Summary
    cAMP showed a dose-related tendency, the response to the im injection being significantly higher than that to the two lowest doses of intranasal sCT (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  10. 10HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, intramuscular sCT produced a higher cAMP response than the middle intranasal dose (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, intramuscular sCT increased cAMP more than the middle intranasal dose.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasecAMP response versus intranasal 100 IU
    Study

    n = 16

    Comparator
    100 IU intranasal sCT
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    50 IU · intramuscularAs given in this study (human).

    Source sentences

    Summary
    cAMP showed a dose-related tendency, the response to the im injection being significantly higher than that to the two lowest doses of intranasal sCT (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  11. 11HumanNon-randomized trialActivity measurement

    In premenopausal and early postmenopausal women, serum calcium changed significantly after 100 IU intranasal sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum calcium changed significantly after 100 IU intranasal sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum calcium
    Study

    n = 16

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    100 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  12. 12HumanNon-randomized trialActivity measurement

    In premenopausal and early postmenopausal women, serum calcium changed significantly after 200 IU intranasal sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum calcium changed significantly after 200 IU intranasal sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum calcium
    Study

    n = 16

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    200 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  13. 13HumanNon-randomized trialActivity measurement

    In premenopausal and early postmenopausal women, serum calcium changed significantly after 50 IU intramuscular sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum calcium changed significantly after 50 IU intramuscular sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum calcium
    Study

    n = 16

    Outcome group
    Bone and joint · Endocrine and hormones
    Studied dose
    50 IU · intramuscularAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  14. 14HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after 100 IU intranasal sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after 100 IU intranasal sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum beta-endorphin
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  15. 15HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after 200 IU intranasal sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after 200 IU intranasal sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum beta-endorphin
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    200 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  16. 16HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after 50 IU intramuscular sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after 50 IU intramuscular sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSerum beta-endorphin
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    50 IU · intramuscularAs given in this study (human).

    Source sentences

    Summary
    Total serum calcium and serum beta-endorphin revealed significant changes after all four administrations (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  17. 17HumanNon-randomized trialMechanism

    In premenopausal and early postmenopausal women, cAMP increased by 10% after the two highest intranasal sCT doses (100 and 200 IU) (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, cAMP rose by 10% after the two highest intranasal sCT doses.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasecAMP
    Study

    n = 16

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 IU and 200 IU · intranasalAs given in this study (human).

    Measurements

    cAMP increase
    10%
    two highest intranasal sCT doses (100 and 200 IU)

    Source sentences

    Summary
    After the two highest intranasal and the im doses cAMP increased 10% and 35%, respectively (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  18. 18HumanNon-randomized trialPharmacokinetics

    In premenopausal and early postmenopausal women, 200 IU intranasal sCT significantly increased plasma sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, 200 IU intranasal sCT significantly increased plasma sCT (P less than 0.05).

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasePlasma sCT
    Study

    n = 16

    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    200 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    All administrations except the 50 IU intranasal dose produced significant increases in plasma sCT (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  19. 19HumanNon-randomized trialPharmacokinetics

    In premenopausal and early postmenopausal women, 50 IU intramuscular sCT significantly increased plasma sCT (P less than 0.05).

    In plain wordsIn premenopausal and early postmenopausal women, 50 IU intramuscular sCT significantly increased plasma sCT (P less than 0.05).

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasePlasma sCT
    Study

    n = 16

    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    50 IU · intramuscularAs given in this study (human).

    Source sentences

    Summary
    All administrations except the 50 IU intranasal dose produced significant increases in plasma sCT (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.
  20. 20HumanNon-randomized trialPharmacokinetics

    In premenopausal and early postmenopausal women, 50 IU intranasal sCT did not significantly increase plasma sCT.

    In plain wordsIn premenopausal and early postmenopausal women, 50 IU intranasal sCT did not significantly increase plasma sCT.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changePlasma sCT
    Study

    n = 16

    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    50 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    All administrations except the 50 IU intranasal dose produced significant increases in plasma sCT (P less than 0.05).
    1 context sentence
    Summary · context
    We investigated the acute, dose-response to three intranasal doses of salmon calcitonin (sCT) (50 IU, 100 IU, and 200 IU) and one im dose (50 IU) in eight premenopausal and eight early postmenopausal women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.